Bicycle Therapeutics plcBCYCNASDAQ
Loading
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -50.00% | -30.44% | -48.91% | -68.81% | +338.49% |
| Gross Profit Growth | -902.91% | -1082.25% | -342.16% | -827.58% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +74.32% | +62.78% | +62.59% | +33.20% | +0.46% |
| Weighted Average Shares Diluted Growth | +74.32% | +62.78% | +62.59% | +33.20% | +0.46% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +235.60% | +48.31% | +18.72% | +30.16% | +16.01% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +56.06% | +60.73% | +61.55% | -21.30% | -23.36% |
| Book Value per Share Growth | +14.59% | +31.34% | +27.89% | -42.53% | -25.92% |
| Debt Growth | -75.73% | -78.88% | -79.19% | -81.31% | -48.20% |
| R&D Expense Growth | +21.06% | +11.37% | +69.40% | +77.31% | +21.05% |
| SG&A Expenses Growth | +17.28% | +39.66% | +27.17% | +19.86% | +4.16% |